1. "Elsevier Inc."
Formats
  1. Journal Article (7386)
  2. Meeting Abstract (4694)
  3. Review (617)
  4. Book Section (538)
  5. Editorial (250)
  6. Conference Paper (138)
  7. Correspondence (92)
  8. Guidelines (82)
  9. Research Letter (29)
  10. Miscellaneous (15)
  11. Book Whole (14)
Groups
  1. Department of Medicine (4610)
  2. Surgery (3546)
  3. Survivorship Research (2658)
  4. Solid Tumor Oncology Division (2651)
  5. Radiation Oncology, Department of (2158)
  6. GSK Faculty (1937)

More Groups

People
  1. Nadeem Abu-Rustum (464)
  2. Dennis Chi (420)
  3. Nancy Lee (409)
  4. Michael Zelefsky (401)
  5. Sergio Giralt (384)
  6. John Mulhall (377)

More People

Years
  1. 2025 (240)
  2. 2024 (784)
  3. 2023 (762)
  4. 2022 (794)
  5. 2021 (723)
  6. 2020 (714)

More Years

Publications
  1. International Journal of Radiation Oncology, Biology, Physics (2610)
  2. Gynecologic Oncology (1197)
  3. Journal of Thoracic Oncology (967)
  4. Biology of Blood and Marrow Transplantation (815)
  5. European Journal of Cancer (524)
  6. Journal of Sexual Medicine (435)

More Publications

Publishers
  1. Elsevier Inc. (13855)

Results (13855)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Using patient-level data from electronic health records to replicate PFS outcomes for four 1L NSCLC trials
    Meeting Abstract

    Bretscher, M.; Machado, R.; Ton, T.; Pal, N.; Trinh, H.; Mahrus, S.; Riely, G.
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • Risk factors associated with pulmonary toxicities from multiple courses of lung stereotactic body radiation therapy (SBRT)
    Meeting Abstract

    Li, X.; Yorke, E.; Jackson, A.; Yue, Y.; Shaverdian, N.; Gelblum, D.; Gomez, D.; Rimner, A.; Simone, C.; Wu, A.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • Phase II study of TKIs as neo(adjuvant) therapy in stage II-III resectable NSCLC with ALK, ROS1, NTRK or BRAFV600 alterations
    Meeting Abstract

    Lee, J.; Wistuba, I.; Ngiam, C.; Yu, W.; Schulze, K.; Rocha, M.; Bara, I.; Carbone, D.; Johnson, B.; Kwiatkowski, D.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • Neoadjuvant osimertinib with/without chemotherapy vs chemotherapy for EGFR mutated resectable NSCLC: NeoADAURA
    Meeting Abstract

    Tsuboi, M.; Weder, W.; Escriu, C.; Blakely, C.; He, J.; Dacic, S.; Yatabe, Y.; Zeng, L.; Walding, A.; Chaft, J.
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • Radiotherapy-associated CT imaging as a potential screening tool for COVID-19
    Meeting Abstract

    Wu, A.; Plodkowski, A.; Ginsberg, M.; Shin, J.; Laplant, Q.; Shepherd, A.; Shaverdian, N.; Ng, V.; Yue, Y.; Gilbo, P.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • Dynamics of molecular markers in EGFR-mutated NSCLC patients treated with patritumab deruxtecan (HER3-DXd; U3-1402)
    Meeting Abstract

    Jänne, P.; Baik, C.; Hayashi, H.; Su, W.; Qi, Z.; Enomoto, K.; Karnoub, M.; Yu, C.; Qiu, Y.; Yu, H. A.
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • HERTHENA-Lung01: A randomized phase 2 study of patritumab deruxtecan (HER3-DXd; U3-1402) in previously treated metastatic EGFR-mutated NSCLC
    Meeting Abstract

    Janne, P.; Johnson, M.; Goto, Y.; Yang, J. C.; Karam, S.; Chen, S.; Qiu, Y.; Yu, H.; Yu, C.
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • Tepotinib safety in MET exon 14 (METex14) skipping NSCLC: Updated results from the VISION trial
    Meeting Abstract

    Veillon, R.; Sakai, H.; Le, X.; Felip, E.; Garassino, M. C.; Cortot, A.; Smit, E.; Park, K.; Griesinger, F.; Britschgi, C.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • Combination osimertinib plus selpercatinib for EGFR-mutant non-small cell lung cancer (NSCLC) with acquired RET fusions
    Meeting Abstract

    Rotow, J.; Patel, J.; Hanley, M.; Yu, H.; Goldman, J.; Nechustan, H.; Scheffler, M.; Awad, M.; Clifford, S.; Santucci, A.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • Neratinib-based combination therapy in her2-mutant lung adenocarcinomas: Findings from two international phase 2 studies
    Meeting Abstract

    Li, B.; Gandhi, L.; Besse, B.; Jhaveri, K.; Mazières, J.; Boni, V.; Shapiro, G.; Waqar, S.; Viteri, S.; Park, H.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save